AbbVie's Cariprazine (VRAYLAR®) Met Primary Endpoint in Phase 3 Study as an Adjunctive Treatment for Major Depressive Disorder
Go back to AbbVie's Cariprazine (VRAYLAR®) Met Primary Endpoint in Phase 3 Study as an Adjunctive Treatment for Major Depressive Disorder| AbbVie (NYSE: ABBV) | Delayed: 251.96 -4.5 (1.75%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $256.46 | 52 Week High | $68.12 | |||
| Open | $251.84 | 52 Week Low | $50.71 | |||
| Day High | $254.62 | P/E | 54.66 | |||
| Day Low | $248.86 | EPS | $4.61 | |||
| Volume | 1,752,206 | |||||
